Amgen stock pre-market at EUR 374.43: plus 0.34 percent

Amgen stock was at EUR 374.43 pre-market on September 30, 2026, up 0.34 percent versus the prior close at Lang & Schwarz. A report also discussed positive Phase 3 dazodalibep results.

Amgen stock was at EUR 374.43 pre-market at 8:01 a.m. CEST on September 30, 2026, according to Lang & Schwarz. The price was up 0.34 percent versus the prior close of EUR 373.15 at Lang & Schwarz.

Clinical development in focus

A September 22, 2026 report published by Yahoo Finance said Amgen had reported positive Phase 3 results for dazodalibep in Sjögren's disease. The report said the OASIZ 301 study met its primary endpoint through Week 48 in patients with moderate to severe disease.

The same report said Amgen had received an FDA label update for IMDELLTRA that reduced recommended monitoring times for the first two doses from 22 to 24 hours to 6 to 8 hours. The clinical developments are dated September 22 and precede the September 30 pre-market quote.